Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Director | June 02, 2023 | June 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date June 02, 2023 · Filed June 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.96 · Expires 2033-06-01 | Direct | 18,475 |
Reported balance
After 2023-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-02 · Grant · Acquired 18,475 · Balance 18,475 F1: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2023 Filed Jun 2, 2023 17:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 18,475 | $0.00 Strike: $38.96 | $0.00 |
DisclosureSEC source: 0000950170-23-026169 · ownership.xml · derivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,475 Underlying: Common Shares · 18,475 shares Expires 2033-06-01 F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting. Read SEC document |
| June 01, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · derivative · entry 19 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 45,000 shares Expires 2025-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The shares subject to the options are fully vested and exercisable. Read SEC document |
| June 01, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,318 | $0.00 Strike: $7.69 | $0.00 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · derivative · entry 18 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,682 Underlying: Common Shares · 9,318 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The shares subject to the options are fully vested and exercisable. Read SEC document |
| June 01, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 24,255 | $38.78 | $940,608.90 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 15 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.78 to $38.81, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 01, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 20,745 | $38.53 | $799,304.85 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 14 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,255 F8 · price: Represents the closing price of the Company's common shares on May 31, 2023 for purposes of net settlement calculations. Read SEC document |
| June 01, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 45,000 | $17.76 | $799,200.00 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 13 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 7,458 | $38.97 | $290,638.26 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 12 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| June 01, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,860 | $38.53 | $71,665.80 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 11 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,458 F8 · price: Represents the closing price of the Company's common shares on May 31, 2023 for purposes of net settlement calculations. Read SEC document |
| June 01, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 9,318 | $7.69 | $71,655.42 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 10 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · derivative · entry 17 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 50,000 shares Expires 2025-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The shares subject to the options are fully vested and exercisable. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 29,835 | $0.00 Strike: $9.85 | $0.00 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · derivative · entry 16 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 29,835 shares Expires 2024-01-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F10 · derivative.exercise_date: The shares subject to the options are fully vested and exercisable. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 26,856 | $38.69 | $1,039,058.64 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 9 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.50 to $38.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 23,144 | $38.37 | $888,035.28 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 8 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,856 F5 · price: Represents the closing price of the Company's common shares on May 30, 2023 for purposes of net settlement calculations. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 50,000 | $17.76 | $888,000.00 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 7 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 23,670 | $38.81 | $918,632.70 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 6 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.66 to $39.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 6,165 | $38.37 | $236,551.05 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 5 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,670 F5 · price: Represents the closing price of the Company's common shares on May 30, 2023 for purposes of net settlement calculations. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 29,835 | $9.85 | $293,874.75 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 4 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 12,000 | $38.53 | $462,360.00 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 3 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.20 to $38.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 19,000 | $39.90 | $758,100.00 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 2 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 19:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 18,006 | $38.63 | $695,571.78 |
DisclosureSEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,000 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.50 to $39.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 18:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,864 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001209191-23-017636 · doc4.xml · derivative · entry 8 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 30,864 shares Expires 2023-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F5 · derivative.exercise_date: The shares subject to the options are fully vested and exercisable. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 18:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 41,152 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001209191-23-017636 · doc4.xml · derivative · entry 7 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 41,152 shares Expires 2023-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F5 · derivative.exercise_date: The shares subject to the options are fully vested and exercisable. F6 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 18:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 8,242 | $36.94 | $304,459.48 |
DisclosureSEC source: 0001209191-23-017636 · doc4.xml · nonDerivative · entry 6 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,006 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.89 to $37.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 18:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,618 | $37.13 | $60,076.34 |
DisclosureSEC source: 0001209191-23-017636 · doc4.xml · nonDerivative · entry 5 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,248 F2 · price: Represents the closing price of the Company's common shares on March 6, 2023 for purposes of net settlement calculations. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 18:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 30,864 | $2.59 | $79,937.76 |
DisclosureSEC source: 0001209191-23-017636 · doc4.xml · nonDerivative · entry 4 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 18:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 10,990 | $37.01 | $406,739.90 |
DisclosureSEC source: 0001209191-23-017636 · doc4.xml · nonDerivative · entry 3 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,002 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.93 to $37.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 18:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 2,160 | $37.13 | $80,200.80 |
DisclosureSEC source: 0001209191-23-017636 · doc4.xml · nonDerivative · entry 2 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,992 F2 · price: Represents the closing price of the Company's common shares on March 6, 2023 for purposes of net settlement calculations. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 18:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 41,152 | $2.68 | $110,287.36 |
DisclosureSEC source: 0001209191-23-017636 · doc4.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| August 16, 2022 Filed Aug 16, 2022 17:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 20,000 | $38.87 | $777,400.00 |
DisclosureSEC source: 0001209191-22-046015 · doc4.xml · nonDerivative · entry 6 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.70 to $39.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 16, 2022 Filed Aug 16, 2022 17:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 32,058 | $38.29 | $1,227,500.82 |
DisclosureSEC source: 0001209191-22-046015 · doc4.xml · nonDerivative · entry 5 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.6431 to $38.6033, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 17:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 33,942 | $37.76 | $1,281,649.92 |
DisclosureSEC source: 0001209191-22-046015 · doc4.xml · nonDerivative · entry 4 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,058 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.5022 to $38.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 17:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 1,000 | $39.15 | $39,150.00 |
DisclosureSEC source: 0001209191-22-046015 · doc4.xml · nonDerivative · entry 3 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,000 Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 17:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 47,000 | $38.60 | $1,814,200.00 |
DisclosureSEC source: 0001209191-22-046015 · doc4.xml · nonDerivative · entry 2 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,000 F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.1397 to $39.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 17:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 43,135 | $37.91 | $1,635,247.85 |
DisclosureSEC source: 0001209191-22-046015 · doc4.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.1353 to $38.1084, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 17:48 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $30.11 | $0.00 |
DisclosureSEC source: 0001209191-22-039837 · doc4.xml · derivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 16:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001209191-22-018457 · doc4.xml · derivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,500 | $30.50 | $76,250.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 19 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,135 Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,500 | $30.55 | $76,375.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 18 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,635 F11 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.55 to $30.65, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,500 | $30.20 | $75,500.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 17 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,135 Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,500 | $30.10 | $75,250.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 16 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,635 Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,500 | $3.80 | $9,500.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 15 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,135 F10 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.800 to $30.880, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,051 | $30.60 | $62,760.60 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 14 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,635 Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 21:41 UTC Amendment | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,500 | $30.80 | $77,000.00 |
DisclosureSEC source: 0001209191-22-017418 · doc4a.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,135 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.800 to $30.880, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,576 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · derivative · entry 21 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,576 shares Expires 2022-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F12 · derivative.exercise_date: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2012 Vesting Commencement Date. F13 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,500 | $30.55 | $76,375.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 13 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,686 Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 7,500 | $30.50 | $228,750.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 12 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,186 Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,500 | $30.52 | $76,300.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 11 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,686 Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 4,516 | $30.44 | $137,467.04 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 10 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,186 F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.40 to $30.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 4,516 | $30.45 | $137,512.20 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 9 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,702 F8 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.4100 to $30.4750, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 4,517 | $30.49 | $137,723.33 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 8 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,218 F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.480 to $30.645, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.